Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,623 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: normal saline solution placebo Clear all

Conditions: Depression, Post Traumatic Stress Disorder
Interventions: Lanicemine, Placebo; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 21 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epstein-Barr Virus Infection
Interventions: mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 482 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 34
States / cities: Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more

Conditions: Heart Failure, Kidney Disease
Interventions: TRV120027, Normal Saline; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Orlando, Florida • Minneapolis, Minnesota • Durham, North Carolina + 1 more

Conditions: Pain, Sciatic Block
Interventions: Placebo, Dexamethasone 4 mg, Dexamethasone 8 mg; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Equinus Contracture
Interventions: Botulinum toxin type A, sodium chloride; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more

Conditions: Vitamin D Deficiency
Interventions: Placebo, 800 IU/day vitamin D supplementation with feedings in the first 28 days after birth, Usual Care; Dietary Supplement · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 24 Hours to 96 Hours
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
Interventions: IV Ganciclovir, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 14
States / cities: Denver, Colorado • Chicago, Illinois • Springfield, Massachusetts + 10 more

Conditions: Cystic Fibrosis
Interventions: N6022, Normal saline; Drug
Lead sponsor: Nivalis Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 17
States / cities: Birmingham, Alabama • Anchorage, Alaska • Palo Alto, California + 14 more

Conditions: Complex Regional Pain Syndromes
Interventions: Ketamine, Midazolam, Normal Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2099
U.S. locations: 1
States / cities: Stanford, California

Conditions: D3 Dopamine Receptor, Cocaine-dependent, Healthy Volunteer
Interventions: [18F]FTP PET/CT; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Kidney Diseases
Interventions: YSPSL, placebo; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 15
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 11 more

Conditions: Lymphoma, Non-Hodgkin
Interventions: Copanlisib (BAY80-6946), Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Bendamustine, Prednisone; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 551 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 10
States / cities: Chandler, Arizona • West Covina, California • Denver, Colorado + 6 more

Conditions: Shingles, Herpes Zoster
Interventions: Zostavax, HZ/su vaccine, Placebo; Biological
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Injury of Body of Pancreas
Interventions: Secretin, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 10,994 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 109
States / cities: Birmingham, Alabama • Guntersville, Alabama • Huntsville, Alabama + 93 more

Conditions: Facial Rhytides, Crow's Feet Lines, Glabellar Lines
Interventions: normal saline, onabotulinumtoxinA 44 U, onabotulinumtoxinA 24 U; Drug · Biological
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 684 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Lumbar Spine Degeneration, Cervical Spine Degeneration
Interventions: saline 0.9%, (0.05% chlorhexidine gluconate (CHG) in sterile water); Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Covid19
Interventions: VIR-7831 (sotrovimab), Placebo; Biological · Drug
Lead sponsor: Vir Biotechnology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,057 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 63
States / cities: Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more

Conditions: Respiratory Failure
Interventions: Midazolam, Normal saline, Fentanyl; Drug
Lead sponsor: Javier Gelvez, MD; Other
Eligibility: Up to 18 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Inguinal Herniorrhaphy
Interventions: CPL-01, Naropin 150 MG Per 20 ML Injection, Placebo; Drug
Lead sponsor: Cali Pharmaceuticals LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 2 more

Conditions: Autism, Severe Behavior Disorder
Interventions: placebo, glutathione, glutathione, vit C and NAC; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 5 Years to 16 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Neuritis, Radiofrequency Ablation
Interventions: Dexamethasone 4 mg/ml, Normal saline; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

NMDA Receptor Modulation for Hyperarousal in PTSD

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

Study to Evaluate TRV120027 on Renal Pharmacodynamics in Patients With Heart Failure and Renal Dysfunction

Trial Comparing Duration of Analgesia After Popliteal Fossa Sciatiac Nerve Block With Ropivacaine 0.5% When Combined With Placebo, Dexamethasone 4mg or Dexamethasone 8 mg

The Effect of Botulinum Toxin A Injections on Ankle Dorsiflexion Following Internal Fixation of Tibial Pilon Fractures

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

ViDES Trial (Vitamin D Extra Supplementation)

Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Ketamine and Midazolam Infusions for CRPS: Feasibility Study

Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT

YSPSL for Prevention of Delayed Graft Function Part B

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)

Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds

Secretin Infusion to Prevent Pancreatic Leaks Following Pancreatic Resection

Moderna Vaccine mRNA-1345 Observational Respiratory Syncytial Virus (RSV) Study

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines

Randomized Controlled Trial Comparing Irrisept Versus Normal Saline for Wound Irrigation After Posterior Spine Surgery

VIR-7831 for the Early Treatment of COVID-19 in Outpatients

Cycling of Sedative Infusions in Critically Ill Pediatric Patients

A Phase 2, Randomized, Double-Blind, Dose Escalation Study in Postoperative Pain Open Inguinal Herniorrhaphy

Study of Glutathione, Vitamin C and Cysteine in Children With Autism and Severe Behavior Problems

Post-lesion Administration of Dexamethasone to Prevent the Development of Neuritis After Radiofrequency Ablation